• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [22390 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2023     Scottish Health Technologies Group (SHTG) Living donor transplantation
2023     Scottish Health Technologies Group (SHTG) Outpatient parenteral antimicrobial therapy (OPAT) cost calculator
2023     Scottish Health Technologies Group (SHTG) The cost-effectiveness of the Scottish Hip Fracture Audit
2023     Scottish Health Technologies Group (SHTG) The clinical effectiveness and cost effectiveness of a digital type 2 diabetes remission programme
2023     Scottish Health Technologies Group (SHTG) Outpatient biopsies (re-usable and disposable) equipment for suspicious laryngeal and pharyngeal lesions
2023     Scottish Health Technologies Group (SHTG) Community based respiratory care services for patients with chronic respiratory conditions
2023     Scottish Health Technologies Group (SHTG) Tumour profiling tests to guide chemotherapy decisions in early breast cancer
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: Syphilis - detection, diagnosis, optimal antibiotic use, and follow-up]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: the management of myalgic encephalomyelitis / chronic fatigue syndrome]
2023     NIHR Public Health Research (PHR) programme Impact of a social prescribing intervention in North East England on adults with type 2 diabetes: the SPRING_NE multimethod study
2023     NIHR Public Health Research (PHR) programme A multicomponent psychosocial intervention to reduce substance use by adolescents involved in the criminal justice system: the RISKIT-CJS RCT
2023     NIHR Health Technology Assessment programme Total ankle replacement versus ankle arthrodesis for patients aged 50–85 years with end-stage ankle osteoarthritis: the TARVA RCT
2023     NIHR Health Technology Assessment programme Motivational support intervention to reduce smoking and increase physical activity in smokers not ready to quit: the TARS RCT
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of platelet-rich plasma for the treatment of knee osteoarthritis]
2023     Norwegian Institute of Public Health (NIPH) Treatments for relapsing and/or refractory multiple myeloma. A health technology assessment
2023     Belgian Health Care Knowledge Centre (KCE) Silicone adhesive multilayer foam dressings to prevent hospital-acquired pressure ulcers: a Belgian RCT-based economic evaluation
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for for long-chain acyl-CoA dehydrogenase deficiency (LCHADD) and mitochondrial trifunctional protein deficiency (TFPD)]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for glutaric acidemia type 1 (GA1)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Efgartigimod alfa (Myasthenia Gravis, AChR-antibody+)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Birch Bark Extract (treatment of wounds associated with epidermolysis bullosa (6 months and older))]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: update of the tool for choosing the dosage of monoclonal antibodies targeting PD 1 or PD-L1]
2023     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) Assessment of hip protectors for users at risk of falls
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Early detection tools for emotional distress in adult people with cancer]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Invasive monitoring of pulmonary artery pressure in patients with symptomatic heart failure]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Efficacy and safety of Emotional Freedom Techniques for the treatment of anxiety, depression and post traumatic stress disorders]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Ovarian tissue cryopreservation and transplantation in patients with cancer or benign diseases to fertility preservation]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Evaluation of the lung cancer screening program]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of coronary sinus narrowing device for the treatment of refractory angina]
2023     NIHR Health Technology Assessment programme Views of female genital mutilation survivors, men and health-care professionals on timing of deinfibulation surgery and NHS service provision: qualitative FGM Sister Study
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: cryotherapy for the prevention of taxane-induced peripheral neuropathy]
2023     Agency for Care Effectiveness (ACE) Echinocandins for treating invasive candidiasis
2023     Agency for Care Effectiveness (ACE) Palivizumab for preventing serious lower respiratory tract disease caused by respiratory syncytial virus
2023     Agency for Care Effectiveness (ACE) Inhaled corticosteroids with long acting beta-2 agonists for treating asthma
2023     Agency for Care Effectiveness (ACE) Daratumumab for treating newly diagnosed light chain (AL) amyloidosis
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Eladocagene exuparvovec (Aromatic-L-amino acid decarboxylase (AADC) deficiency, ≥ 18 months)]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: continuum of care and services for individuals with a traumatic spinal cord injury in Québec - characteristics, care pathways and clinical outcomes for adults from 2014 to 2020]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: effectiveness of rehabilitation models and approaches for young people with adjustment problems]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: characteristics and needs of targeted rehabilitation clienteles for young people with adjustment problems aged 10 or older]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: next-generation sequencing (NGS) panels for intellectual disability and global developmental delay - Assessment report on the repatriation of a test performed outside Québec]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Rebinyn – prophylaxis in children and adolescents with hemophilia B]
2023     Health Information and Quality Authority (HIQA) A rapid health technology assessment of gene expression profiling tests for guiding the use of adjuvant chemotherapy in early-stage invasive breast cancer
2023     Health Information and Quality Authority (HIQA) Repatriation of paediatric haematopoietic stem cell transplant services to Ireland: a Health Technology Assessment
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: optimal use of echocardiography in Québec- diagnosis and follow-up of chronic heart failure]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: barriers and facilitators encountered by women living with a physical disability (PD), intellectual disability (ID) or autism spectrum disorder (ASD) when using perinatal services]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vutrisiran (hereditary transthyretin amyloidosis) - Benefit assessment according to § 35a SGB V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) - Addendum to Commission A22-81]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer, after 1 prior therapy) - Addendum to Commission A22-80]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tixagevimab/cilgavimab (COVID-19) - benefit assessment according to § 35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Remdesivir (COVID-19, without supplemental oxygen, < 18 years of age) - benefit assessment according to § 35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Remdesivir (COVID-19, requirement for additional oxygen supply, = 4 weeks - < 12 years of age) - Benefit assessment according to § 35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relugolix (prostate cancer) - Benefit assessment acc. to § 35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ravulizumab (generalized myasthenia gravis) - Benefit assessment according to § 35a SGB V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (renal cell carcinoma) - Addendum to Commission A22-71]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (cervical cancer) - Addendum to Commission A22-70]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lonafarnib (Hutchinson-Gilford progeria syndrome or progeroid laminopathy) - Benefit assessment according to §35a SGB V [1], Sentence 11]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lisocabtagene maraleucel (DLBCL, PMBCL and FL3B) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Faricimab (visual impairment due to diabetic macular oedema) - Benefit assessment acc. to § 35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Faricimab (neovascular age-related macular degeneration) - Benefit assessment according to § 35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (HIV infection, 2 to < 6 years) - Benefit assessment according to §35a Social Code Book V]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiate diagnostic measures in the presence of symptoms and signs suggestive of urinary tract infection (cystitis and pyelonephritis) and initiate first-line pharmacological treatment for cystitis in an individual 14 years of age and older]
2023     Belgian Health Care Knowledge Centre (KCE) Evaluation of digital medical technologies
2023     Penn Medicine Center for Evidence-based Practice (CEP) Update: Clinical risk prediction tools for venous thromboembolism in medical patients
2023     Scottish Health Technologies Group (SHTG) Bacteriophage therapy for patients with difficult to treat bacterial infections
2023     Health Technology Wales (HTW) Renal denervation to treat people with resistant hypertension
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: wound care-assessment, management, and optimal treatment use]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: effectiveness of rehabilitation models and approaches for young people with adjustment problems]
2023     Health Information and Quality Authority (HIQA) Health technology assessment of the addition of severe combined immunodeficiency (SCID) to the National Newborn Bloodspot Screening Programme
2023     Norwegian Institute of Public Health (NIPH) [Triclosan coated sutures for prevention of surgical site infection: a health technology assessment]
2023     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Update: Functioning and disability - An evidence map]
2023     Norwegian Institute of Public Health (NIPH) 177Lu-PSMA-617 for treatment of metastatic castration resistant prostate cancer: a health technology assessment
2023     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Evondos® medicine-dispensing service
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality in revision surgery (knee)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality for total knee replacement]
2023     Ontario Health Supplemental Screening as an Adjunct to Mammography for Breast Cancer Screening in People With Dense Breasts
2023     Ontario Health Placental growth factor (PlGF)-based biomarkers for risk prediction in people with suspected preeclampsia
2023     Ontario Health Wire-free, nonradioactive localization techniques to guide surgical excision of nonpalpable breast cancer tumours
2023     Ontario Health Testing for homologous recombination deficiency in patients diagnosed with ovarian cancer
2023     Ontario Health Bariatric surgery for people with class I obesity and poorly controlled type 2 diabetes
2023     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Effects of treatment and social support measures in comorbidity]
2023     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Evaluation of taking mifepristone at home during a medical abortion]
2023     Norwegian Institute of Public Health (NIPH) [Surgery for degenerative rotator cuff tears: a health technology assessment]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Robotic Bronchoscopy for Lung Nodule Diagnostics. Horizon Scanning Technologies]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Electromagnetic Navigation Bronchoscopy: Use in Dying for Lung Nodules Resection. Horizon Scanning Technologies]
2023     Health Technology Wales (HTW) Multi-grip myoelectric upper-limb prosthetics
2023     Health Technology Wales (HTW) Robot-assisted thoracic surgery
2022     Haute Autorite de sante (HAS) [Transcranial magnetic stimulation (rTMS) in the treatment of adult treatment-resistant depression]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Developmental vision disorders: do children and adolescents benefit from active vision training?]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mobility disorders: does the Feldenkrais method help?]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blood values: do older people benefit from regular determination of vitamin B12 and vitamin D levels in the blood?]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Social isolation in the elderly: what measures can prevent or counteract social isolation?]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Heart disease in children: can children be helped to cope with their illness through psychological support?]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cystitis: do herbal remedies help with recurring, uncomplicated cystitis?]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Depression in children and adolescents: does psychotherapy lead to better results compared to other therapies?]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Advanced lymphoedema: can non-medicinal procedures relieve symptoms?]
2022     National Institute for Health and Care Excellence (NICE) Esketamine nasal spray for treatment-resistant depression. NICE technology appraisal guidance 854
2022     National Institute for Health and Care Excellence (NICE) Avatrombopag for treating primary chronic immune thrombocytopenia. NICE technology appraisal guidance 853
2022     National Institute for Health and Care Excellence (NICE) Trifluridinetipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments. NICE technology appraisal guidance 852
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer. NICE technology appraisal guidance 851